Effect of Patient Management Based on Continuous Continuous Glucose Monitoring on Major Adverse Cardiovascular Events in Patients With Type 2 Diabetes and Moderate to Severe Coronary Artery Stenosis

Launched by SECOND AFFILIATED HOSPITAL, SCHOOL OF MEDICINE, ZHEJIANG UNIVERSITY · Sep 23, 2023

Keywords

ClinConnect Summary

This clinical trial is studying how different methods of managing blood sugar levels can affect heart health in patients with type 2 diabetes who also have significant narrowing of their coronary arteries. Participants will be divided into two groups: one group will use a continuous glucose monitoring system (which tracks blood sugar levels in real-time) to guide their treatment, while the other group will follow standard management based on a blood test known as HbA1c. The main goal is to see which method better reduces the risk of serious heart events, such as heart attacks or strokes.

To participate in this study, individuals need to be between 35 and 75 years old, have type 2 diabetes with an HbA1c level between 7.5% and 10%, and have moderate to severe narrowing of their coronary arteries. They should also have had a stable blood sugar management plan for the past three months. Participants can expect to have their blood sugar monitored regularly over two years, and both groups will receive care according to established diabetes guidelines. This trial is still in the planning stages and is not yet recruiting participants.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Male or female between 35 and 75 years old type 2 diabetes HbA1C: 7.5%-10% Moderate to severe coronary artery stenosis (the degree of stenosis of any major coronary artery is ≥50% as assessed by coronary angiography or coronary CTA) The blood sugar lowering regimen has been stable in the past 3 months Ability to understand the requirements of the study and provide informed consent
• Exclusion Criteria:
• • Type 1 diabetes or other types of diabetes Acute myocardial infarction or stroke within the past three months Ketoacidosis, hyperosmolar hyperglycemic state Relative or absolute contraindications to contrast agent examinations such as severe renal insufficiency, contrast agent allergy, and hyperthyroidism Elective surgery planned within 2 years Preparing for pregnancy or becoming pregnant Life expectancy less than 2 years Skin allergies and other situations where CGM cannot be used Currently participating in other clinical studies